Harness the Next Generation of Vectors to Guarantee Targeted, Specific, Efficient and Safe Gene Delivery
The 2nd Annual Next Generation Gene Therapy Vectors Summit is dedicated to overcoming the current immunogenicity, toxicity and manufacturability challenges facing the field by pioneering the next generation of superior delivery vectors.
Industry pioneers from cutting edge biopharma and world-leading academic vectorology groups including Voyager Therapeutics, Spark Therapeutics, Dyno Therapeutics, Chameleon Biosciences, BioMarin and more will share clinically meaningful insights on how to enhance existing vectors and pioneer radical novel approaches to deliver genes more efficiently and safely.
Spanning a range of delivery approaches from cutting-edge AAV capsid optimisation, utilising lenti and other viral vectors, to innovative non-viral gene therapy approaches, this comprehensive event will enable you to reduce immunogenicity, improve tissue targeting, simplify manufacturing and enhance the safety profile of your approach.
Everything in gene therapy starts with delivery, so join this definitive, niche conference to delve into the details of vector design, engineering and optimization case studies, equipping you with the insights required to deliver transformative therapeutics to patients more effectively and safely than ever before.
Group discounts and early booking rates are available. Please visit the website for full pricing information.
Speakers: Leah Byrne, Assistant Professor of Ophthalmology, University of Pittsburgh, Genine Winslow, CEO, Chameleon Biosciences, Annahita Kervala, Head of Gene Therapy, CODA Biotherapeutics, Alexis Cockroft, Independent Consultant, Asif Paker, VP Clinical Development, Swan Bio, Bob Getts, CSO, Code Biotherapeutics, Bojiao Yin, Associate Director, Process Development, Elevate Bio, Brandon Wheeler, Senior Scientist, Capsida Bio, Charlie Albright, CSO, Affinia Therapeutics, Dale Ludwig, CSO, Gennao Bio, Diem Nguyen, CEO, Xalud Therapeutics, Don Haut, CEO, Carmine Therapeutics, Dwaipayan Sen, Associate Director Vector Development and Production, Astellas Gene Therapies, Eric Kelsic, CEO, Dyno Therapeutics, Giuseppe Ronzitti, Group Leader, Genethon, Jack Rychak, CSO, Poseida, Jacob Smith, Sr Director of Process Development, AskBio, Jeron Chen, Scientist, Biogen, John Thompson, VP Genomics and Computational Biology, Homology Medicine, Jose Lora, CSO, Intergalactic Tx, Kalina Paunovska, Researcher, Georgia Institute, Kei Kishimoto, CSO, Selecta Bioscience, Kyle Grant, Director Vector Production, Voyager Therapeutics, Lauren Kaskiel, CBO, Code Biotherapeutics, Lawrence Tam, Group Leader Vector Engineering Group, Gyroscope Therapeutics, Li Oh, Associate Director of Gene Therapy, Capsida Biotherapeutics, Matthew Fuller, Director, Vector Platform Research, Ultragenyx, Melissa Kotterman, VP Head of Discovery, 4DMT, Niren Murthy, Professor of Bioengineering, University of California at Berkeley, Peixin Zhu, VP Discovery and Research, Logic Bio, Peter Pechan, Gene Therapy Leader, Pierre Burguiere, Independent Consultant, Pooja Agarwal, Executive Director Gene Therapy Research, BioMarin, Rodolphe Clerval, CEO, Coave Therapeutics, Ryan Burnett, Collaborative Leader in Development and CMC Strategy, Neurocrine, Sean Armour, Head of Discovery, Spark Therapeutics, Udo Maier, Head of Research Beyond Borders, Boehringer Ingelheim, Veronica Ferrer, Senior Project Leader, Vivet Therapeutics, Vivian Choi, Head of Global Gene Therapy Research, Takeda, Xavier Anguela, Deputy CSO, AskBio Europe
Schedule:
08:00 - 16:30